thiotepa has been researched along with Rhabdomyosarcoma, Embryonal in 1 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Rhabdomyosarcoma, Embryonal: A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiotepa was administered at a daily dose of 300 mg/m2 for 3 consecutive days." | 2.69 | High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study. ( Boutard, P; Lafay-Cousin, L; Méchinaud, F; Oberlin, O; Plouvier, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lafay-Cousin, L | 1 |
| Plouvier, P | 1 |
| Méchinaud, F | 1 |
| Boutard, P | 1 |
| Oberlin, O | 1 |
1 trial available for thiotepa and Rhabdomyosarcoma, Embryonal
| Article | Year |
|---|---|
High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Combined Modality Therapy; D | 2000 |